Golgi-localised Guanylate-binding protein 5 enhances glycolysis in macrophages

This study demonstrates that the Golgi-localized GTPase GBP5 is essential for maintaining Golgi integrity and driving glycolytic flux, glucose uptake, and cytokine production in IFN-γ-stimulated macrophages, thereby playing a critical role in immunometabolism.

The Gist

Imagine your body's immune system as a highly trained special forces unit. When an invader (like a virus or bacteria) is detected, these soldiers—called macrophages—need to switch into "high alert" mode immediately. To do this, they need a massive amount of energy, much like a race car switching from cruising speed to full throttle.

This paper is about a specific protein inside these immune cells called GBP5. Think of GBP5 as the chief mechanic of the immune cell's engine room.

Here is the story of what the researchers discovered, broken down into simple terms:

1. The Engine Needs Fuel (Glycolysis)

When macrophages get the "fight" signal (from a molecule called Interferon-gamma), they switch their energy source. Instead of slowly burning fuel like a diesel truck (mitochondria), they switch to a high-octane, fast-burning fuel called glycolysis. This process turns sugar (glucose) into quick energy and a waste product called lactate.

The researchers found that GBP5 is essential for this engine to run.

• Without GBP5: The immune cell's engine sputters. It can't take in enough sugar, and it produces very little energy. It's like trying to drive a Ferrari with a clogged fuel line.
• With GBP5: The engine roars to life, burning sugar efficiently to power the immune response.

2. The "Mechanic" Lives in the Control Tower (The Golgi)

Where does this mechanic (GBP5) hang out? It lives in a part of the cell called the Golgi apparatus.

• The Analogy: Imagine the cell is a busy factory. The Golgi is the shipping and packaging department. It takes raw materials, packages them, and ships them out to the cell's surface where they are needed.
• The Discovery: The researchers found that GBP5 specifically sits in the "cis-Golgi" (the receiving dock of the shipping department).
• What happens if the mechanic is gone? When they removed GBP5, the shipping department fell apart. The packaging machines (the Golgi) broke into tiny, scattered fragments. Even though the factory wasn't smaller, the organization was a mess. This chaos meant the cell couldn't properly package and send out the tools it needed to fight infection.

3. The "GTPase" Switch

GBP5 isn't just a static statue; it's a machine that needs to be turned on. It has a built-in switch called GTPase activity.

• The Analogy: Think of GBP5 as a smart key for a car. You can have the key (the protein), but if the battery in the key is dead (the GTPase activity is broken), the car won't start.
• The Finding: The researchers tried to put a "broken key" (a mutant version of GBP5 that couldn't switch on) into the cells. It didn't work. The immune cells still couldn't burn sugar or fight effectively. This proves that the action of the protein is just as important as its presence.

4. The Result: A Weakened Soldier

Because the engine (glycolysis) was broken and the shipping department (Golgi) was fragmented, the immune cells couldn't do their job properly.

• They couldn't display their "fight flags" (surface markers like CD80) to call for backup.
• They couldn't shout loud enough (produce cytokines like IL-6 and TNF) to warn other cells of the danger.

The Big Picture

This study changes how we see these proteins. Previously, scientists thought GBP5 was mostly a weapon used directly against viruses and bacteria. This paper shows that GBP5 is actually a metabolic manager.

It ensures that when an immune cell decides to fight, it has:

1. The fuel (sugar burning).
2. The organization (intact Golgi).
3. The communication tools (cytokines and surface markers).

In short: GBP5 is the unsung hero that keeps the immune system's engine running smoothly and its factory organized, ensuring our body can mount a strong defense against infections. Without it, our immune soldiers are left with a broken engine and a messy workshop, unable to fight effectively.

Technical Summary

1. Problem Statement

Guanylate-binding proteins (GBPs) are a family of large, interferon-gamma (IFN$\gamma$)-inducible GTPases known primarily for their roles in host defense against intracellular pathogens and the induction of programmed cell death (e.g., pyroptosis). While their pathogen-specific functions are well-characterized, their broader impact on the metabolic reprogramming of frontline immune cells remains unexplored. Macrophages rely heavily on a metabolic switch from oxidative phosphorylation to glycolysis upon pro-inflammatory (M1) activation to fuel immune responses. The authors sought to determine if human GBPs (specifically GBP1-5) regulate this critical glycolytic flux and the associated M1 macrophage phenotype.

2. Methodology

The study employed a multi-faceted approach using human cell models and advanced metabolic profiling:

• Cell Models:
  • THP-1 Macrophages: A human monocytic cell line differentiated into macrophages using PMA.
  • Primary Monocyte-Derived Macrophages (MDMs): Isolated from healthy donor blood, differentiated with GM-CSF, and polarized to the M1 phenotype using IFN$\gamma$ and LPS.
• Genetic Manipulation:
  • Knockdown: Transient silencing via siRNA (siGBP1-5) and stable silencing via miRNA30E-based shRNA (shGBP2, shGBP3).
  • Knockout: CRISPR-Cas9 mediated deletion of GBP2 and GBP5 ($\Delta$GBP2, $\Delta$GBP5).
  • Rescue/Overexpression: Doxycycline-inducible expression of Wild-Type (WT) GBP5 and a GTPase-deficient mutant (GBP5$^{K51A-52AA}$).
• Metabolic Assays:
  • Seahorse XF Analysis: Measured Oxygen Consumption Rates (OCR) for mitochondrial respiration and Extracellular Acidification Rates (ECAR) for glycolysis. Specifically, Glycolytic Proton Efflux Rate (GlycoPER) was calculated to isolate glycolytic flux from mitochondrial CO$_2$ contribution.
  • Metabolite Quantification: Glucose consumption and lactate production were measured in supernatants using a Nova Biomedical analyzer.
  • Isotopic Tracing: Cells were cultured with [U-$^{13}$C$_6$]-Glucose. Metabolites were analyzed via LC-MS and GC-MS to trace carbon flow through glycolysis, the TCA cycle, and the pentose phosphate pathway.
  • NMR Spectroscopy: Used for extracellular metabolite profiling of supernatants.
• Phenotypic and Structural Analysis:
  • Flow Cytometry: Assessed surface expression of M1 markers (CD80, CD86, CD64) and IFN$\gamma$ receptor.
  • Cytokine Profiling: ELISA for IL-6 and TNF production.
  • Immunofluorescence & Microscopy: Structured Illumination Microscopy (SIM) was used to visualize GBP5 localization relative to Golgi markers (GM130, Giantin, Golgin97) and to assess Golgi fragmentation.

3. Key Contributions

• Discovery of Metabolic Regulation: Identified GBP2 and GBP5 as critical positive regulators of glycolysis in IFN$\gamma$-stimulated human macrophages.
• Specific Role of GBP5 in M1 Phenotype: Demonstrated that while both GBP2 and GBP5 regulate glycolysis, only GBP5 deficiency impairs the classical M1 activation phenotype (reduced CD80 surface expression and cytokine production).
• Mechanistic Insight: Established that the GTPase activity of GBP5 is essential for its metabolic and phenotypic functions.
• Subcellular Localization & Architecture: Confirmed GBP5's predominant localization to the cis-Golgi in macrophages and revealed that GBP5 is required to maintain Golgi integrity (preventing fragmentation).
• Metabolic Flux Specificity: Showed that GBP5 deficiency specifically disrupts glucose uptake and lactate production without significantly altering TCA cycle carbon flux or mitochondrial respiration.

4. Key Results

• Glycolytic Regulation:

  • Silencing or knockout of GBP2 and GBP5 significantly reduced basal, induced, and compensatory glycolysis in both THP-1 and primary MDMs.
  • Mitochondrial respiration (OCR) remained unchanged, indicating the effect is specific to glycolysis.
  • Overexpression of WT GBP5 in IFN$\gamma$-stimulated cells paradoxically reduced glycolysis, suggesting a complex dosage-dependent regulation or "soaking up" of regulatory factors (GDIs), whereas the GTPase-deficient mutant had no such effect.

• M1 Phenotype and Cytokines:

  • GBP5 deficiency led to a significant reduction in surface CD80 expression and decreased secretion of IL-6 and TNF upon IFN$\gamma$/LPS stimulation.
  • GBP2 deficiency did not affect CD80 or IL-6/TNF levels, despite reducing glycolysis, suggesting GBP5 has a unique role in coupling metabolism to the inflammatory phenotype.

• Metabolic Tracing and Flux:

  • Glucose/Lactate: GBP5-deficient cells consumed less glucose and produced less lactate.
  • Isotopic Tracing: [U-$^{13}$C$_6$]-Glucose tracing revealed a significant decrease in glycolytic intermediates (Glucose-6-phosphate, Pyruvate, Lactate) and a reduction in M+3 isotopomers.
  • TCA Cycle: Surprisingly, TCA cycle intermediates (Citrate, Succinate, Fumarate, Malate) showed stable isotopic labeling, indicating that while glycolysis is blocked, the remaining pyruvate entering the mitochondria is processed normally.
  • Alternative Pathways: Elevated levels of Ribose-5-phosphate (suggesting pentose phosphate pathway shifts) and Glycerol (suggesting altered lipid turnover/fatty acid mobilization) were observed in GBP5-deficient cells.

• Localization and Golgi Integrity:

  • GBP5 co-localized predominantly with GM130 (cis-Golgi).
  • The GTPase-deficient mutant (GBP5$^{K51A-52AA}$) showed reduced cis-Golgi localization.
  • Golgi Fragmentation: GBP5-deficient macrophages exhibited increased Golgi fragmentation (more fragments, same total area), suggesting GBP5 stabilizes Golgi architecture.

5. Significance

This study fundamentally expands the understanding of Guanylate-binding proteins beyond their canonical role in pathogen restriction. It establishes GBP5 as a critical immunometabolic regulator that links the Golgi apparatus to the glycolytic flux required for effective macrophage activation.

• Therapeutic Potential: By identifying GBP5 as a regulator of the M1 phenotype and glycolysis, it offers a potential new therapeutic target for modulating inflammatory diseases (e.g., sepsis, autoimmune disorders) where macrophage metabolism is dysregulated.
• Mechanistic Novelty: The finding that GBP5 stabilizes the cis-Golgi and that this structural integrity is dependent on GTPase activity provides a new mechanism for how GTPases regulate cellular metabolism, potentially via the trafficking of glucose transporters (GLUT1/3) or other metabolic enzymes.
• Distinction from Antiviral Roles: The study highlights a functional divergence: while GBP5's antiviral role against HIV (inhibiting furin processing) is GTPase-independent and occurs at the trans-Golgi, its role in macrophage homeostasis and glycolysis is GTPase-dependent and occurs at the cis-Golgi.

In summary, the paper defines GBP5 as a Golgi-localized GTPase essential for sustaining the glycolytic flux and inflammatory capacity of human macrophages, bridging the gap between innate immune signaling, organelle architecture, and cellular metabolism.